<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The <z:e sem="disease" ids="C0024796" disease_type="Disease or Syndrome" abbrv="MFS|MFS1">Marfan syndrome</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MFS</z:e>) is a systemic <z:e sem="disease" ids="C0009782" disease_type="Disease or Syndrome" abbrv="">connective tissue disorder</z:e> caused by mutations in the FBN1 gene </plain></SENT>
<SENT sid="1" pm="."><plain>Recent molecular studies, most performed in mouse models, revealed that the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MFS</z:e> is more a developmental abnormality with broad and complex effects on the morphogenesis and function of multiple organ systems </plain></SENT>
<SENT sid="2" pm="."><plain>FBN1 haploinsufficiency and dysregulated transforming growth factor-beta (TGF-β) signaling seem to be critical for clinical manifestations in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MFS</z:e> including <z:hpo ids='HP_0002616'>aortic root dilatation</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>Aortic root <z:hpo ids='HP_0002617'>aneurysm</z:hpo> and <z:hpo ids='HP_0002647'>aortic dissection</z:hpo> represent the main causes of morbidity and mortality in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MFS</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>Most importantly, TGF-β antagonism through <z:chebi fb="0" ids="2719,48432">angiotensin II</z:chebi> type 1 receptor blockers (ARBs), for example <z:chebi fb="0" ids="6541">losartan</z:chebi>, has been shown to prevent and possibly reverse <z:hpo ids='HP_0002616'>aortic root dilatation</z:hpo> in a mouse model of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MFS</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>A first human study on a small pediatric cohort confirmed those promising results in reducing the aortic root growth over a follow-up period of 12 to 47 months </plain></SENT>
<SENT sid="6" pm="."><plain>So, a large multicenter trial has been set up and results should be available soon </plain></SENT>
<SENT sid="7" pm="."><plain>Other therapeutic strategies which might be combined with <z:chebi fb="0" ids="6541">losartan</z:chebi> include traditional β-blockade, <z:chebi fb="0" ids="50845">doxycyclin</z:chebi> and <z:chebi fb="0" ids="35664">statins</z:chebi> </plain></SENT>
<SENT sid="8" pm="."><plain>Such management could offer the first potential for primary prevention of clinical manifestations in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MFS</z:e> </plain></SENT>
</text></document>